Management Change – Form 8-K
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
1-6028 |
35-1140070 |
||
(State or other jurisdiction |
(Commission |
( |
||
of incorporation) |
File Number) |
Identification No.) |
(Address of principal executive offices) (
Registrant's telephone number, including area code: (484) 583-1400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
__________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol(s) |
|
Common Stock |
LNC |
|
Depositary Shares, each representing a 1/1000th interest in a share of 9.000% Non-Cumulative Preferred Stock, Series D |
LNC PRD |
|
__________________________________
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
The material terms and conditions of the 2020 Plan are described in the Company's Proxy Statement filed with the
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
The foregoing summary of the Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Bylaws attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Company's 2023 Annual Meeting was held on
Item 1.Election of Directors
The eleven nominees for election to the Board were elected, each for a term expiring at the Company's 2024 Annual Meeting of Shareholders, based upon the following votes:
Director Nominee |
For |
Against |
Abstentions |
Broker Non-Votes |
|
109,192,183 |
8,807,341 |
548,287 |
23,929,526 |
|
106,456,237 |
8,032,918 |
4,058,655 |
23,929,526 |
|
109,166,112 |
8,672,063 |
709,636 |
23,929,526 |
|
115,084,389 |
2,982,214 |
481,207 |
23,929,526 |
|
109,358,505 |
8,716,982 |
472,324 |
23,929,526 |
|
111,321,832 |
6,720,426 |
505,554 |
23,929,526 |
|
109,986,289 |
7,951,542 |
609,980 |
23,929,526 |
|
115,094,886 |
2,943,486 |
509,439 |
23,929,526 |
|
113,792,466 |
4,275,012 |
480,333 |
23,929,526 |
|
109,808,725 |
8,020,705 |
718,381 |
23,929,526 |
|
115,787,547 |
2,250,315 |
509,949 |
23,929,526 |
Item 2.Ratification of Auditors
The proposal to ratify the appointment of
For |
Against |
Abstentions |
133,633,920 |
8,143,987 |
699,430 |
There were no broker non-votes for this item.
Item 3.Advisory Resolution on Executive Compensation
The proposal to approve an advisory resolution regarding the compensation paid to the Company's named executive officers, as disclosed in the Company's 2023 Proxy Statement, was approved based on the following votes:
For |
Against |
Abstentions |
Broker Non-Votes |
92,923,253 |
24,621,844 |
1,002,714 |
23,929,526 |
Item 4.Advisory Proposal Regarding Frequency of Future Advisory Resolutions on Executive Compensation
A one-year frequency was approved, on an advisory basis, with respect the proposal regarding the frequency (every one, two or three years) of future advisory resolutions on the compensation of the Company's named executive officers, based on the following votes:
One Year |
Two Years |
Three Years |
Abstentions |
Broker Non-Votes |
114,524,883 |
314,809 |
2,538,389 |
581,573 |
24,512,977 |
Item 5.Approval of Amendment to
The proposal to approve the Amendment to the 2020 Plan was approved based on the following votes:
For |
Against |
Abstentions |
Broker Non-Votes |
82,569,774 |
35,131,526 |
846,511 |
23,929,526 |
Item 6.Non-Binding Shareholder Proposal Regarding Independent Board Chair
The non-binding shareholder proposal to amend the Company's corporate governance documents to require an independent board chair was not approved based on the following votes:
For |
Against |
Abstentions |
Broker Non-Votes |
54,622,341 |
63,173,840 |
751,630 |
23,929,526 |
Item 7.Non-Binding Shareholder Proposal Regarding Ratification of Executive Termination Pay
The non-binding shareholder proposal requesting that the Board seek shareholder approval or ratification of new or renewed executive pay packages that provide for severance or termination payments with an estimated value exceeding 2.99 times the sum of the executive's base salary plus short-term bonus was not approved based on the following votes:
For |
Against |
Abstentions |
Broker Non-Votes |
18,543,483 |
99,330,674 |
668,949 |
23,929,526 |
Item 9.01. Financial Statements and Exhibits.
(c) |
Exhibits. |
Exhibit Number |
Description |
3.1 |
Amended and Restated Bylaws of the Company, effective |
10.1* |
|
104 |
Cover Page Interactive Data File (embedded with the Inline XBRL document). |
_____________
* This exhibit is a management contract or a compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|||||
By |
/s/ |
||||
|
|
||||
Title: |
Senior Vice President and Secretary |
Date:
Attachments
Disclaimer
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
Where the boys aren't — college graduations
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News